News GW Pharma's marijuana-based epilepsy drug approved in US The FDA has approved UK-based GW Pharmaceuticals' drug for a rare form of childhood epilepsy - the first marijuana-based medicine approved in the US.
News FDA advisers back GW's Epidiolex for rare epilepsy UK firm's potential blockbuster on course for approval
News GW files cannabis-based epilepsy drug in EU and US After Sativex disappointment, Epidiolex could transform GW's fortunes.
News NeuroPace brain implant reduces epilepsy seizures in long-te... Data also suggests treatment could improve memory
News UCB recruits Belgian wearables firm for epilepsy study Byteflies' Sensor Dot will help monitor brain, heart and respiration activity.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.